VERAXA Biotech Seeks Partners for BiTAC Cancer Platforms at BIO International Convention

VERAXA Biotech AG (NASDAQ: VRXA) is highlighting partnering opportunities for its proprietary BiTAC-ADC and BiTAC-TCE technology platforms ahead of the BIO International Convention, taking place June 22-25 in San Diego. The company recently reported new proof-of-concept data supporting its BiTAC-ADC platform, which is designed to improve cancer treatment precision through tumor-restricted activation of therapeutic agents while minimizing off-target toxicity.

According to the press release, these findings, together with previously presented BiTAC-TCE data unveiled at the American Association for Cancer Research Annual Meeting in April 2026, support the potential of two differentiated cancer therapy platforms that may be applicable across multiple solid tumor indications. Management plans to discuss partnering opportunities for both technologies at the BIO International Convention, scheduled for June 22-25, 2026, in San Diego.

The BiTAC-ADC platform represents a novel approach to antibody-drug conjugates, aiming to restrict the activation of the therapeutic agent to the tumor microenvironment. This could potentially reduce the systemic side effects often associated with traditional chemotherapy. The BiTAC-TCE platform, on the other hand, focuses on bispecific T cell engagers, which redirect a patient’s own immune T cells to attack cancer cells. Together, these platforms offer a dual strategy for tackling solid tumors, which have historically been more challenging to treat with immunotherapies than blood cancers.

VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. The company is building a pipeline of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats, guided by rigorous quality-by-design principles.

The news is significant because it signals VERAXA’s readiness to move beyond preclinical development and into collaborative partnerships that could accelerate clinical testing and eventual commercialization. For investors, the announcement provides a glimpse into the company’s strategic direction and potential value drivers. The full press release and additional updates are available in the company’s newsroom at http://ibn.fm/VRXA.

As the BIO International Convention approaches, industry observers will be watching for any partnership announcements that could validate the BiTAC platforms and propel VERAXA into the next phase of growth. The company’s focus on precision oncology aligns with broader trends in cancer research, where the goal is to develop therapies that are more effective and less toxic than conventional treatments.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is VERAXA Biotech Seeks Partners for BiTAC Cancer Platforms at BIO International Convention.

The post VERAXA Biotech Seeks Partners for BiTAC Cancer Platforms at BIO International Convention appeared first on citybuzz.